Difference Capital Reports Fourth Quarter and Full Year

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
1,746
Difference Capital Reports Fourth Quarter and Full Year 2018 Results

TORONTO, April 01, 2019 (GLOBE NEWSWIRE) -- Difference Capital Financial Inc. (“ DCF ” or the “ Company ”) ( TSX:DCF ), today reports its financial results for the three months and year ended December 31, 2018.

Full Year and Fourth Quarter 2018 Financial Highlights

  • The portfolio produced a gross gain of $4.9 million for the fourth quarter and $2.0 million for the full year 2018, primarily driven by write-ups in the Company’s Vena Solutions Inc. (“Vena”) and Ethoca Solutions Inc. (“Ethoca”) investments plus unrealized foreign exchange gains on U.S. dollar denominated assets, partially offset by fair value losses in six private positions.
  • Net asset value 1 per share as of December 31, 2018 is $7.21.  This compares to $6.58 at September 30, 2018, and $7.74 at December 31, 2017.
  • Net income for the fourth quarter was $3.6 million or $0.62 per share and net loss for 2018 was $3.2 million or $0.55 per share compared to net income of $4.0 million or $0.69 per share for fourth quarter of 2017 and a loss of $1.2 million or $0.20 per share for the year 2017.
  • In March 2018, the Company sold its indirect stake in the 618 acre undeveloped land known as the Eagle in Rancho Mirage, California for initial gross proceeds of approximately $14.3 million.
  • The Company also sold its common and preferred shares in Thunderbird Entertainment Inc. (“Thunderbird”) in March 2018, generating net proceeds of $5.75 million.
  • The Company issued a $6.7 million non-brokered private placement of 12% senior debentures maturing June 30, 2020 (the “Private Debentures”).
  • In June and July 2018, the Company redeemed all $29.2 million of its 8% unsecured convertible debentures maturing July 31, 2018 (the “Convertible Debentures”).

2019 Successful Exits

  • As announced on January 9, 2019, the Company sold the majority of its stake in Vena Solutions Inc. and generated approximately $13 million.
  • As a result of the Vena sale, the Company was able to redeem all of the Private Debentures in full later that month.
  • On March 12, 2019, Ethoca announced that it was being acquired. The Company expects to receive proceeds of at least $10 million in the second quarter and a further contribution to net asset value of $4.3 million on the sale of its Ethoca shares.
  • When the Ethoca transaction closes, the company expects to have approximately $12.6 million in cash ($2.20 per common share) and no debt.
(figures are in $000 except per share amounts and shares outstanding)   Q4 2018     FY 2018     Q4 2017     FY 2017  
Net gain (loss) on investments and marketable securities   4,860     1,959     5,201     3,202  
Other income   67     448     298     1,611  
Total Portfolio Contribution   4,927     1,997     5,499     4,813  
         
Total expenses and financing costs   (1,317 )   (5,213 )   (1,472 )   (5,994 )
         
Net income (loss)   3,610     (3,216 )   4,027     (1,181 )
Earnings (loss) per share $ 0.62   $ (0.55 ) $ 0.69   $ (0.20 )
      FY 2018       FY 2017  
Total assets      64,466       77,033  
Total liabilities     22,519       31,995  
Net asset value     41,947       45,038  
Shares outstanding     5,815,924       5,816,721  
Net asset value per share   $ 7.21     $ 7.74  
Share price   $ 3.30     $ 3.75  
                 

2018 Review

During 2018, the Company generated liquidity from the disposition of its U.S. real estate and Thunderbird investments, and the $6.7 million Private Debenture offering. The Company was therefore able to fully redeem the $29.2 million in principal amount of its 8% convertible unsecured debentures (the “Convertible Debentures”) outstanding on or before July 31, 2018.

The Company benefited from a large valuation gain on Vena, the majority of which was sold in January 2019, equating to a life-to-date return of 4X capital invested. Positive developments at Ethoca and secondary market activity supported a significant valuation increase in this holding in 2018. Subsequent to the year-end, an S&P 100 financial services firm announced that it entered into an agreement to acquire Ethoca. The Company achieved a 4X disposition on its TouchBistro Inc. ("TouchBistro") investment after three years, albeit on a small investment of $250,000. Valuation decreases on six of its private company holdings, five of which occurred in the fourth quarter, pushed the Company to a loss for the year. During 2018, the Company sold $4.0 million of Mogo Finance Technology Inc. (“Mogo”) convertible debentures and purchased $5.9 million of Mogo common shares.

For the year ended December 31, 2018, the Company realized $0.6 million of net capital gain on investments and marketable securities.  The realized capital gain was primarily attributed to the disposition of the Company’s investment in TouchBistro ($0.8 million).  The realized gains were partially offset by realized loss on the sale of Thunderbird preferred shares.

For the year ended December 31, 2018, the Company recorded $0.9 million of unrealized gain on investments and marketable securities. The significant changes in unrealized gain of the Company’s investment portfolio during the year were as follows: an $8.3 million increase in the valuation of Vena Solutions due to the Vena’s significant financing that closed in early January 2019, and to which the Company sold the majority of its Vena common shares; a $2.7 million valuation increase in Ethoca Solutions based on comparison of its operating metrics to comparable companies; and $1.6 million in unrealized currency gain on the Company’s U.S. dollar denominated assets; offset by: a reduction in value of Mogo common shares of $4.2 million; a reduction in unrealized gain in Mogo convertible debentures of $0.8 million; and unrealized fair value reductions ranging between $0.6 million and $1.4 million each for Baanto, Blue Ant, BrainScope, Carta Worldwide, ScribbleLive, and Waterloo Innovation Network LP, totalling $5.6 million.

Net income for the quarter ended December 31, 2018 was $3.6 million, or $0.62 per share compared to a net income of $4.0 million, or $0.69 per share for the quarter ended December 31, 2017 and a net loss of $0.8 million, or $0.15 per share for the quarter ended September 30, 2018.

For the three months ended December 31, 2018, the Company had a net realized loss on disposition of investments and marketable securities of $0.1 million, compared to a realized gain on disposition of $0.4 million during the same period last year and a realized loss of $0.0 million during the third quarter of 2018.

For the three months ended December 31, 2018, the Company recorded $5.0 million of unrealized gain on investments and marketable securities, compared to an unrealized gain of $4.8 million during the same period last year and an unrealized gain of $0.1 million during the third quarter of 2018.  The significant changes in unrealized gain (loss) of the Company’s investments and marketable securities during the quarter were as follows: the Company recorded an unrealized gain of $8.3 million on its Vena investment; an unrealized gain of $2.7 million on its Ethoca investment; and, an unrealized currency gain on its U.S. dollar denominated assets of $0.6 million; offset by marked-to-market losses of publicly listed investments and marketable securities including Mogo of $2.0 million; and, fair value write-downs on investments in Baanto, Blue Ant, BrainScope, Cardiac Dimensions, Carta, and Waterloo Innovation Network LP totalling $4.0 million.

Total expenses for the year ended December 31, 2018 were $5.2 million, compared to $6.0 million for the year ended December 31, 2017. The significant components of expenses were as follows: financing costs for the year ended December 31, 2018 were $2.2 million compared to $3.2 million during the same period in 2017, as the Company redeemed its Convertible Debentures on June 15 and July 31 but also incurred interest on its Private Debentures issued on June 21, 2018; compensation expense for the year ended December 31, 2018 was $1.6 million versus $1.3 million in 2017 as the Company accrued for severance costs in 2018 associated with terminating its acting CFO; and, professional fees - which include audit, legal, accounting and directors’ fees - for the year ended December 31, 2018 were $0.9 million compared to $0.8 million in 2017.

2019 Outlook

Thanks to two significant transactions announced after the year-end, Vena and Ethoca, we have excess cash on the balance sheet and no debt for the first time since 2013. We will continue to seek opportunities to prudently monetize investments and generate cash to reinvest into selective existing holdings, new private opportunities and undervalued small-capitalization public technology companies. We are not expecting any further industry trade sales in the next two to three quarters, nor any immediate IPO exits from our portfolio. However, industry merger and acquisition activity in the next 9 to 18 months is quite possible, as are the opportunities for secondary sales.

Please refer to the section regarding forward-looking statements which form an integral part of this release. These results, along with the audited financial statements and the company's MD&A, are available on the company's website at www.differencecapital.com and on SEDAR at www.sedar.com .

About Difference Capital Financial Inc.

Difference Capital Financial Inc. invests in and advises growth companies. We leverage our capital market expertise to help unlock value in technology, media and healthcare companies as they approach important milestones in their business lifecycle.

Caution Regarding Forward-Looking Statements

Certain statements contained in this press release may be deemed “forward-looking statements.” Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “scheduled,” “will seek,” “towards,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although DCF believes that the expectations reflected in those forward-looking statements are reasonable, no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. These statements speak only as of the date of this press release. DCF undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, other than as required by applicable law.

1 Net asset value (“NAV”) is a non-IFRS financial measure and is calculated by subtracting the aggregate fair value of the liabilities of the Company from the aggregate fair value of its assets. Net asset value per share is calculated by dividing NAV by the number of common shares outstanding as at the measurement date. The term net asset value per share does not have any standardized meaning according to IFRS and therefore may not be comparable to similar measures presented by other companies.

Contact Information

Henry Kneis Chief Executive Officer (416) 649-5090 www.differencecapital.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 2

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading
Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Launch: Le Monde Gourmand Now Available in the UK

Updated Category News Views 330

Le Monde Gourmand Expands into the UK Market Fragrance enthusiasts in the UK have some delightful news to celebrate! Le Monde Gourmand has officially launched at a leading online retailer. With a diverse range of indulgent scents to choose from, customers can finally enjoy the luxury of these unique fragrances. A Treasure Trove of Scents Le Monde Gourmand's collection...

Continue Reading
Fashion Footwear LLC Wins Landmark Case Against Iconix Brand Group

Updated Category News Views 459

Landmark Decision for Fashion Footwear LLC In a landmark decision that has the potential to reshape the dynamics of the fashion licensing landscape, a New York Appellate Court has decisively ruled in favor of Fashion Footwear LLC, stating that the actions of US Pony Holdings ("Pony"), an affiliate of Iconix Brand Group, to terminate their exclusive footwear license were...

Continue Reading
Vertical Bridge and Verizon: A $3.3 Billion Milestone Deal

Updated Category News Views 270

Vertical Bridge Partners with Verizon for Massive Tower Acquisition Vertical Bridge REIT, LLC, a notable name in communications infrastructure, has secured a significant agreement with Verizon Communications Inc. This $3.3 billion transaction gives Vertical Bridge exclusive rights to manage and operate over 6,300 wireless communication towers across the country. This...

Continue Reading
Insights into the Salary Trends for TD Professionals in 2025

Updated Category News Views 124

Understanding the Salary Benchmarks for TD Professionals Recent ATD research delves into the compensation and benefits of Training and Development (TD) professionals. In 2025, the overall average salary for TD professionals reached $101,229, while the median salary stood at $95,000, as indicated by the latest findings from ATD. Key Findings from the ATD Salary Report TD...

Continue Reading
Inventiva Prepares for Major Combined General Meeting Insights

Updated Category News Views 137

Inventiva Announces Preparatory Documents for Shareholders Daix, France; New York City, NY – Inventiva (Euronext Paris and Nasdaq: IVA) is a clinical-stage biopharmaceutical company dedicated to developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH). They have recently made available key preparatory documents for their Combined General...

Continue Reading